Immune surveillance in glioblastoma: Role of the NKG2D system and novel cell-based therapeutic approaches

被引:16
作者
Chitadze, Guranda [1 ]
Kabelitz, Dieter [2 ]
机构
[1] Univ Hosp Schleswig Holstein UKSH, Dept Internal Med 2, Unit Hematol Diagnost, Kiel, Germany
[2] Univ Hosp Schleswig Holstein UKSH, Inst Immunol, Kiel, Germany
关键词
adoptive cell transfer; gamma; delta T cells; glioblastoma; immunotherapy; NK cells; NKG2D ligand; receptor; DELTA-T-CELLS; I-RELATED CHAIN; NEWLY-DIAGNOSED GLIOBLASTOMA; GROWTH-FACTOR-BETA; NK CELLS; TGF-BETA; ANTIGEN RECEPTOR; LIGANDS CONTRIBUTES; DOWN-REGULATION; SOLUBLE MICB;
D O I
10.1111/sji.13201
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Glioblastoma, formerly known as glioblastoma multiforme (GBM), is the most frequent and most aggressive brain tumour in adults. The brain is an immunopriviledged organ, and the blood-brain barrier shields the brain from immune surveillance. In this review, we discuss the composition of the immunosuppressive tumour micromilieu and potential immune escape mechanisms in GBM. In this respect, we focus on the role of the NKG2D receptor/ligand system. NKG2D ligands are frequently expressed on GBM tumour cells and can activate NKG2D-expressing killer cells including NK cells and gamma delta T cells. Soluble NKG2D ligands, however, contribute to tumour escape from immunological attack. We also discuss the current immunotherapeutic strategies to improve the survival of GBM patients. Such approaches include the modulation of the NKG2D receptor/ligand system, the application of checkpoint inhibitors, the adoptive transfer of ex vivo expanded and/or modified immune cells or the application of antibodies and antibody constructs to target cytotoxic effector cells in vivo. In view of the multitude of pursued strategies, there is hope for improved overall survival of GBM patients in the future.
引用
收藏
页数:20
相关论文
共 214 条
  • [1] HER2-Specific T Cells Target Primary Glioblastoma Stem Cells and Induce Regression of Autologous Experimental Tumors
    Ahmed, Nabil
    Salsman, Vita S.
    Kew, Yvonne
    Shaffer, Donald
    Powell, Suzanne
    Zhang, Yi J.
    Grossman, Robert G.
    Heslop, Helen E.
    Gottschalk, Stephen
    [J]. CLINICAL CANCER RESEARCH, 2010, 16 (02) : 474 - 485
  • [2] Incorporating Tumor-Associated Macrophages into Engineered Models of Glioma
    Akins, Erin A.
    Aghi, Manish K.
    Kumar, Sanjay
    [J]. ISCIENCE, 2020, 23 (12)
  • [3] Down-regulation of the human major histocompatibility complex class I chain-related gene A (MICA) and its receptor is mediated by microRNA-146b-5p and is a potential mechanism of immunoediting in papillary thyroid carcinoma
    Al-Abdallah, Abeer
    Jahanbani, Iman
    Mehdawi, Heba
    Ali, Rola H.
    Al-Brahim, Nabeel
    Mojiminiyi, Olusegun
    Junaid, Thamradeen A.
    [J]. EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2020, 113
  • [4] Delta One T Cells for Immunotherapy of Chronic Lymphocytic Leukemia: Clinical-Grade Expansion/Differentiation and Preclinical Proof of Concept
    Almeida, Afonso R.
    Correia, Daniel V.
    Fernandes-Platzgummer, Ana
    da Silva, Claudia L.
    da Silva, Maria Gomes
    Anjos, Diogo Remechido
    Silva-Santos, Bruno
    [J]. CLINICAL CANCER RESEARCH, 2016, 22 (23) : 5795 - 5804
  • [5] [Anonymous], HLA ALLELES NUMBERS
  • [6] [Anonymous], INCB7839 TREATING CH
  • [7] [Anonymous], ENSEMBL GRCH37 RELEA
  • [8] [Anonymous], 2016, BLOOD
  • [9] [Anonymous], 1 IN HUMAN STUDY ICT
  • [10] Natural Killer Cell Cytotoxicity Is Suppressed by Exposure to the Human NKG2D Ligand MICA*008 That Is Shed by Tumor Cells in Exosomes
    Ashiru, Omodele
    Boutet, Philippe
    Fernandez-Messina, Lola
    Agueera-Gonzalez, Sonia
    Skepper, Jeremy N.
    Vales-Gomez, Mar
    Reyburn, Hugh T.
    [J]. CANCER RESEARCH, 2010, 70 (02) : 481 - 489